Altitude Online: The Business of Neuroscience & Psychedelics
"Be here now." — Ram Dass
Editorial
Altitude People Series, Week 3 — Business: The Billionaire Who Built a Psychedelics Company on One Mushroom Trip
Christian Angermayer didn't drink or use drugs until a single psilocybin experience. A decade later he had co-founded atai, helped start Compass and sold to Eli Lilly for $2.8 billion. Here's his story, in his words, alongside Steve Jobs, Sam Altman, Bob Parsons, Tim Ferriss, Bryan Johnson and Sergey Brin.
Nathan Richardson • Nov 11, 2026
Research
One Dose, Years of Relief? What Psilocybin Trials Found in People With Cancer
Research
How Long Does Relief Last? Antidepressants vs. Psychedelics, by the Numbers
Policy Nov 9, 2026
The Day After Approval: Which States Will Let Doctors Prescribe Psilocybin
Policy Nov 7, 2026
After the Election, the Fights Move Indoors: ICER, a Courtroom and a New Drug Law for Psilocybin
Policy Nov 4, 2026
What the 2026 Midterms Mean for Psychedelics: Who Won, Who Lost, and Which Compounds Feel It
Personal Story Nov 1, 2026
A Reader's Account: What Mantra Dose Euphoria Did to My Brain and Body
Editorial Oct 28, 2026
Altitude People Series, Week 2 — Politicians: The Lawmakers Who Tried Ibogaine, and Why
Research Jul 29, 2026
Everyone Knows Which Pill They Got. The FDA Just Said What To Do About It.
Wellness Oct 24, 2026
What a "Bad Trip" Actually Is — and What to Do If You're Having One
Editorial Oct 20, 2026
Altitude People Series, Week 1 — Sports: The Athletes Who Went Public About Psychedelics, and Why
Policy Oct 20, 2026
MK-Ultra, Explained: What the CIA Actually Did With "Brainwashing Drugs" — and Why Congress Is Still Asking About It
Research Oct 16, 2026
EMDR: The Therapy Sandra Bullock Calls 'The Most Healing' — and Prince Harry Did on Camera
Editorial Oct 14, 2026
Bicycle Day, Explained: The Three Days in 1943 That Accidentally Invented LSD
Policy Oct 13, 2026
Is DMT Legal in Europe? Here's the Real Answer, Country by Country
Policy Oct 1, 2026
Meet the 7 People Who Actually Lobby for Psychedelics in Washington
Policy Sep 29, 2026
Only 3 of 10 Psychedelic Companies Lobby Washington. One Just Joined — Twice, in the Same Quarter.
Policy Sep 26, 2026
150+ Patents, $113 Million Raised, 4 Employees: Inside the Company Betting It Doesn't Need to Run Its Own Trials
Policy Sep 26, 2026
16 States, 7 New Laws, 11 Dead Bills, Only 2 Still Alive: We Scored the 2026 Psychedelic Legislative Session
Research Sep 23, 2026
Which Psychedelic-Company CEO's Pay Actually Matched Their Stock's Performance? We Checked All 10 — Almost None Did.
Research Sep 22, 2026
How Clinical Trials Actually Work — and What It Means for the Psychedelic Industry
Editorial Sep 26, 2026
The "Nibble It" Problem: What Your Doctor Doesn't Have to Tell You About Off-Label Prescriptions
Editorial Sep 22, 2026
Nausea for 12 Hours vs. Sexual Dysfunction for Years: The Side-Effect Math Nobody's Doing on Mental Health Drugs
Policy Sep 21, 2026
19% of American Adults Have Anxiety. Every Drug Treating It Is a Decades-Old Generic — Here's Who Wins If DT120 Changes That
Policy Sep 17, 2026
The Psychedelic Money Graveyard: Renames, Reverse Mergers, and the Companies That Didn't Make It
Policy Sep 11, 2026
The Psychedelic Money Rankings: $11 Billion Public, $1.6 Billion Private, $140 Million From Governments
Wellness Sep 6, 2026
Permafried
Policy Aug 31, 2026
Ibogaine's Flagship Drug Hit a Cardiac Signal and a Lawsuit. A Different Drug Is Now Leading.
Policy Aug 28, 2026
Ketamine Has More Patents Than Any Compound We Track. So Why Isn't Big Pharma More Interested?
Policy Aug 28, 2026
Altitude Intelligence Brief: Who's Actually Making Money on Depression, Anxiety, and PTSD
Policy Aug 26, 2026
Psychedelics in Uniform: What the Military Did to Soldiers, and What the VA Is Now Asking of Veterans
Policy Aug 26, 2026
LSD Has 14 Patents in Our Tracker. The Company Closest to Approval Owns One.
Policy Aug 24, 2026
The 5-MeO-DMT Patent Race Has a Twist: The Clinical Leader Barely Owns Any of It
Policy Aug 20, 2026
Psilocybin Has 223 Patents in Play. Here's Who Actually Holds Them.
Policy Aug 17, 2026
677 Patents and One FDA Rejection: Mapping the Psychedelic Drug Pipeline
Wellness Aug 11, 2026
I Flushed My Antidepressants in Paradise. I Got Lucky.
Neuroscience Aug 10, 2026
Quick Trip or Daily Practice: The Brain Doesn't Care How You Get There
Editorial Jul 30, 2026
Kambo: The Ceremony That Promises Purification and Delivers Peril
Wellness Jul 29, 2026
I Thought I'd Walked Into a Retirement Community. What I Found Was a Masterclass in How the Brain Stays Young
Research Jul 29, 2026
Eli Lilly Just Paid $3.8 Billion for the Same Molecule People Get From a Toad
Personal Story Jul 31, 2026
Holding Your Breath On Purpose
Personal Story Apr 4, 2026
Love Yourself Five Times: How Psilocybin Changed My Life
Psychedelic Medicine Jul 7, 2026
The Next Psilocybin Question Is Not Hype. It Is Evidence, Timing, and Review.
Neuroscience Mar 28, 2026
Fear Is Not a Character Flaw. It's Architecture.
Neuroscience Mar 21, 2026
Three Paths to a Healthier Brain: Learning, Meditation, and Psychedelics
Policy Mar 14, 2026
Clinical vs. Consumer: Navigating the New Psilocybin Landscape
Editorial Mar 7, 2026
What Is Evidence-Based Healing? A Guide to Altitude Global's Standards
Personal Story Feb 28, 2026
The God Molecule and the Spilled Milk
Research Feb 14, 2026
The Clinical Revolution: Psilocybin and 5-MeO-DMT Move from Underground to Evidence-Based Medicine
Latest News
See AllRegulatory Nov 15, 2026
A Trade-Secrets Fight Over Psilocybin Research Is Headed to Trial, as Compass Awaits the FDA
Regulatory Nov 15, 2026
The Federal Government Will Spend Up to $4.9 Million to Prepare Ibogaine Trials for Veterans With PTSD
Research Nov 14, 2026
Psilocybin Lowered Inflammation for a Month in a Small Parkinson's Study, With Big Caveats
Psychedelics Nov 12, 2026
Johnson & Johnson Co-Leads a $100M Bet on a Psychedelic-Inspired Depression Drug Without the Trip
Psychedelic Stocks
Close Nov 13, 2026- NRXP NRx Pharmaceuticals $2.19 −3.95%
- GHRS GH Research $19.10 +3.30%
- OPTH Optimi Health $2.25 +3.21%
- DFTX Definium Therapeutics $32.08 −2.79%
- CMND Clearmind Medicine $4.53 −1.95%
- DRUG Bright Minds Biosciences $23.11 +1.63%
All 12 companies Not investment advice
More News
See AllRegulatory Nov 12, 2026
Belgium Could Get Its First Legal Psilocybin Treatment Outside a Clinical Trial
Research Nov 12, 2026
Scientists Found a Florida Mushroom That Makes Both Psilocybin and a Deadly Toxin
Psychedelics Nov 12, 2026
A Psychedelic Pharmacist Warns MDMA Could Make It Hard to Urinate for Men With Enlarged Prostates
Regulatory Nov 11, 2026
The DEA Wants 57 Times More Ibogaine Made for Research Next Year
Product of the Day
Calm
Sleep more. Stress less. Live better. The #1 app for sleep, meditation and relaxation.
Encyclopedia
Set and Setting
Mindset and environment shaping the experience.
Example: "Setting" isn't just ambiance — our reporting on overseas clinic safety found that poor setting (unscreened staff, absent medical oversight, patients dosed without preparation) was a common thread across the worst documented outcomes, not just an aesthetic afterthought.
Aa-Zz
Join the Circle
Access the inner sanctum of Altitude. Weekly digests on neuroscience, early access to retreat bookings, and exclusive product drops.
Free Membership • Unsubscribe Anytime